ATE403875T1 - Polypeptid-biomarker zur diagnose von morbus alzheimer - Google Patents

Polypeptid-biomarker zur diagnose von morbus alzheimer

Info

Publication number
ATE403875T1
ATE403875T1 AT03792291T AT03792291T ATE403875T1 AT E403875 T1 ATE403875 T1 AT E403875T1 AT 03792291 T AT03792291 T AT 03792291T AT 03792291 T AT03792291 T AT 03792291T AT E403875 T1 ATE403875 T1 AT E403875T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
diagnosis
human
patients
Prior art date
Application number
AT03792291T
Other languages
English (en)
Inventor
Oezkan Yalkinoglu
Gerhard Koenig
Denis Hochstrasser
Jean-Charles Sanchez
Odile Carrette
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02018283A external-priority patent/EP1394549A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of ATE403875T1 publication Critical patent/ATE403875T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03792291T 2002-08-23 2003-08-11 Polypeptid-biomarker zur diagnose von morbus alzheimer ATE403875T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018283A EP1394549A1 (de) 2002-08-23 2002-08-23 Biomarker zur Diagnose von Alzheimer Erkrankung
EP02026643 2002-11-29

Publications (1)

Publication Number Publication Date
ATE403875T1 true ATE403875T1 (de) 2008-08-15

Family

ID=31947886

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08002793T ATE475888T1 (de) 2002-08-23 2003-08-11 Biomarker zur diagnose von alzheimer
AT03792291T ATE403875T1 (de) 2002-08-23 2003-08-11 Polypeptid-biomarker zur diagnose von morbus alzheimer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08002793T ATE475888T1 (de) 2002-08-23 2003-08-11 Biomarker zur diagnose von alzheimer

Country Status (10)

Country Link
EP (3) EP1953556B1 (de)
JP (1) JP4405919B2 (de)
AT (2) ATE475888T1 (de)
AU (3) AU2003251702B2 (de)
CA (6) CA2745998C (de)
DE (2) DE60322719D1 (de)
DK (3) DK1535076T3 (de)
ES (3) ES2347924T3 (de)
PT (1) PT1535076E (de)
WO (1) WO2004019043A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469312A1 (de) * 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnose der Alzheimer Krankheit
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
US7749716B2 (en) * 2004-05-18 2010-07-06 Vermilllion, Inc. Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease
GB0502068D0 (en) 2005-02-01 2005-03-09 King S College London Screening method
WO2006106115A2 (de) * 2005-04-06 2006-10-12 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnose von alzheimer
ATE511643T1 (de) * 2005-06-16 2011-06-15 Vermillion Inc Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer
CA2689848A1 (en) * 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
JP5357746B2 (ja) * 2006-03-11 2013-12-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 末梢性の動脈疾患のためのバイオマーカーとしてのβ−２ミクログロブリン
GB0616230D0 (en) * 2006-08-16 2006-09-27 Univ Cambridge Tech Biomarkers and uses thereof
EP2117527B1 (de) 2007-02-08 2020-06-17 Med-Life Discoveries LP Verbindungen zur verwendung bei der behandlung von altersdemenz vom alzheimer-typ
EP2279420B1 (de) 2008-03-21 2014-01-29 Manuela G. Neuman VERFAHREN ZUR DIFFERENTIELLEN DIAGNOSE VON MORBUS ALZHEIMER GEGEN FRONTOTEMPORALE DEMENZ MIT FAS-L, TNF-alpha UND ccCK-18 ALS BIOMARKER
EP2344881A4 (de) * 2008-09-26 2012-03-07 Univ Melbourne Biomarker für morbus alzheimer
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
NZ720949A (en) 2013-12-09 2019-03-29 Univ Leland Stanford Junior Methods and compositions for treating aging-associated conditions
GB201322094D0 (en) 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
AU2016279804B2 (en) 2015-06-15 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
KR102572009B1 (ko) * 2020-10-21 2023-08-29 순천향대학교 산학협력단 시스타틴 c를 포함하는 퇴행성 신경 질환 진단용 바이오마커 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
ES2235550T3 (es) * 1998-10-23 2005-07-01 Evotec Neurosciences Gmbh Metodos de diagnosticar o pronosticar la enfermedad de alzheimer.
WO2001063294A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis of bipolar affective disorder (bad) and unipolar depression
WO2001071357A2 (en) * 2000-03-20 2001-09-27 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of breast cancer
EP1325338A2 (de) * 2000-04-03 2003-07-09 Oxford GlycoSciences (UK) Limited Diagnose und behandlung der alzheimerschen krankheit
WO2002082075A2 (de) * 2001-04-06 2002-10-17 Biovision Ag Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
JP2003284574A (ja) * 2001-10-03 2003-10-07 Pfizer Prod Inc 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用

Also Published As

Publication number Publication date
AU2010212316B2 (en) 2012-05-24
DK1953556T3 (da) 2010-10-25
DE60333608D1 (de) 2010-09-09
EP2221620A2 (de) 2010-08-25
CA2745569A1 (en) 2004-03-04
CA2496321E (en) 2004-03-04
PT1535076E (pt) 2008-11-03
EP2221620B1 (de) 2013-10-02
CA2496321A1 (en) 2004-03-04
CA2745731A1 (en) 2004-03-04
DK2221620T3 (da) 2014-01-06
AU2010212316A1 (en) 2010-09-09
DE60322719D1 (de) 2008-09-18
ES2436318T3 (es) 2013-12-30
CA2745731C (en) 2015-05-12
AU2010212317A1 (en) 2010-09-09
WO2004019043A3 (en) 2004-06-24
DK1535076T3 (da) 2008-11-24
ATE475888T1 (de) 2010-08-15
AU2010212317B2 (en) 2013-01-10
CA2745724C (en) 2015-06-02
EP1953556B1 (de) 2010-07-28
CA2745998C (en) 2013-11-26
JP4405919B2 (ja) 2010-01-27
CA2745998A1 (en) 2004-03-04
EP2221620A3 (de) 2010-11-24
WO2004019043A2 (en) 2004-03-04
EP1535076A2 (de) 2005-06-01
AU2003251702A1 (en) 2004-03-11
EP1953556A3 (de) 2008-11-26
CA2496321C (en) 2013-05-21
EP1953556A2 (de) 2008-08-06
CA2746000A1 (en) 2004-03-04
JP2005536729A (ja) 2005-12-02
EP1535076B1 (de) 2008-08-06
ES2311751T3 (es) 2009-02-16
CA2745724A1 (en) 2004-03-04
CA2746000C (en) 2014-10-21
ES2347924T3 (es) 2010-11-25
AU2003251702B2 (en) 2010-06-03
CA2745569C (en) 2015-07-14

Similar Documents

Publication Publication Date Title
ATE403875T1 (de) Polypeptid-biomarker zur diagnose von morbus alzheimer
WO2004058044A3 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
DE60016178D1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
EP0391714A3 (de) Verfahren zum Nachweis der Alzheimer-Krankheit: Untersuchung des nicht-neuralen Gewebes
ATE386942T1 (de) Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer
DK1521774T3 (da) Trunkerede Tau-proteiner
KR930022086A (ko) 아밀로이드 전구체 단백질의 단백질가수분해에 근거한 알츠하이머병(Alzheimer's disease)의 진단분석
DE60332538D1 (de) Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
ATE474227T1 (de) Bestimmung von felinem und caninem probnp
ATE168135T1 (de) Diagnose von retinoblastoma
WO2002088303A3 (en) Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
DE60133661D1 (de) Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen
DE60219645D1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
EP1560025A3 (de) Marker spezifisch für Diabetes
WO2003083078A3 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
WO2004005487A3 (en) Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
JP2006519391A (ja) 自閉症の診断
WO2002077173A3 (en) Polynucleotide encoding a novel immunoglobulin superfamily member, apex4, and variants and splice variants thereof
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
EP1572931A4 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
MXPA03005500A (es) Proteina humana novedosa que contiene una repeticion rica en leucina, expresada predominantemente en intestino delgado, hlrrsi1.
WO2007062363A3 (en) Method for diagnosing a person having sjogren's syndrome
DE60334200D1 (de) Verfahren zur messung von neprilysinaktivität
BR0317224A (pt) Processo de detecção de prp (proteìna priÈnio nativa) com uso de um antibiótico dos aminoglicosìdeos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1535076

Country of ref document: EP

EEIH Change in the person of patent owner